Our previous work unveiled the world's first anti‐TGF‐β/PD‐L1 bispecific antibody (BsAb), known as YM101.[42] YM101 demonstrated remarkable efficacy against various tumor models, particularly those categorized as immune‐excluded tumors. This evidence concerns the gene CD274 and neoplasm.